These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 27720403)

  • 1. Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial.
    Lorvand Amiri H; Agah S; Tolouei Azar J; Hosseini S; Shidfar F; Mousavi SN
    Clin Nutr; 2017 Dec; 36(6):1490-1497. PubMed ID: 27720403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of Non-Alcoholic Fatty Liver by Vitamin D Supplement: A Double-Blind Randomized Controlled Clinical Trial.
    Lorvand Amiri H; Agah S; Mousavi SN; Hosseini AF; Shidfar F
    Arch Iran Med; 2016 Sep; 19(9):631-8. PubMed ID: 27631178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome.
    Asemi Z; Foroozanfard F; Hashemi T; Bahmani F; Jamilian M; Esmaillzadeh A
    Clin Nutr; 2015 Aug; 34(4):586-92. PubMed ID: 25300649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
    Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
    Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled clinical trial comparing calcitriol versus cholecalciferol supplementation to reduce insulin resistance in patients with non-alcoholic fatty liver disease.
    Mahmoudi L; Asadi S; Al-Mousavi Z; Niknam R
    Clin Nutr; 2021 May; 40(5):2999-3005. PubMed ID: 33341312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial.
    Dabbaghmanesh MH; Danafar F; Eshraghian A; Omrani GR
    Diabetes Metab Syndr; 2018 Jul; 12(4):513-517. PubMed ID: 29588137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome.
    Javed Z; Papageorgiou M; Deshmukh H; Kilpatrick ES; Mann V; Corless L; Abouda G; Rigby AS; Atkin SL; Sathyapalan T
    Nutrients; 2019 Jan; 11(1):. PubMed ID: 30658483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D deficiency in non-alcoholic fatty liver disease: The chicken or the egg?
    Lee SM; Jun DW; Cho YK; Jang KS
    Clin Nutr; 2017 Feb; 36(1):191-197. PubMed ID: 26615912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of omega-3 fatty acid supplementation on insulin metabolism and lipid profiles in gestational diabetes: Randomized, double-blind, placebo-controlled trial.
    Samimi M; Jamilian M; Asemi Z; Esmaillzadeh A
    Clin Nutr; 2015 Jun; 34(3):388-93. PubMed ID: 24973862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
    BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
    Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
    Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Turmeric Supplementation Improves Serum Glucose Indices and Leptin Levels in Patients with Nonalcoholic Fatty Liver Diseases.
    Navekar R; Rafraf M; Ghaffari A; Asghari-Jafarabadi M; Khoshbaten M
    J Am Coll Nutr; 2017; 36(4):261-267. PubMed ID: 28443702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients.
    Hu Y; Liu J; Dong X; Xu Y; Leng S; Wang G
    Med Sci Monit; 2016 Nov; 22():4146-4151. PubMed ID: 27803497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
    Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
    Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.
    Mofidi F; Poustchi H; Yari Z; Nourinayyer B; Merat S; Sharafkhah M; Malekzadeh R; Hekmatdoost A
    Br J Nutr; 2017 Mar; 117(5):662-668. PubMed ID: 28345499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study.
    Aller R; Izaola O; Gómez S; Tafur C; González G; Berroa E; Mora N; González JM; de Luis DA
    Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3118-24. PubMed ID: 26367736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic response to omega-3 fatty acid supplementation in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial.
    Soleimani A; Taghizadeh M; Bahmani F; Badroj N; Asemi Z
    Clin Nutr; 2017 Feb; 36(1):79-84. PubMed ID: 26611718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.